<DOC>
	<DOCNO>NCT00062504</DOCNO>
	<brief_summary>To analyze effect Talampanel progression free survival patient recurrent high grade glioma .</brief_summary>
	<brief_title>Phase 2 Trial Using Talampanel Patients With Recurrent High Grade Gliomas</brief_title>
	<detailed_description>To determine efficacy Talampanel patient recurrent malignant glioma measure 6-month progression survival , well obtain preliminary information regard spectrum toxicity drug among patient population .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Astrocytoma</mesh_term>
	<mesh_term>Oligodendroglioma</mesh_term>
	<criteria>Inclusion 1 . Patients histologically prove intracranial malignant glioma eligible protocol . Malignant glioma include glioblastoma multiforme ( GBM ) , anaplastic astrocytoma ( AA ) , anaplastic oligodendroglioma ( AO ) , anaplastic mixed oligoastrocytoma ( AMO ) , malignant astrocytoma NOS ( otherwise specify ) . 2 . Patients must unequivocal evidence tumor progression MRI CT scan . This scan perform within 14 day prior registration steroid dosage stable least 5 day . 3 . Patients undergone recent resection recurrent progressive tumor eligible long follow condition apply : 1 . They recover effect surgery . 2 . Residual disease follow resection recurrent tumor mandate eligibility study . To best assess extent residual disease postoperatively , CT/ MRI do : later 96 hour immediate postoperative period least 4 week postoperatively , within 14 day registration , steroid dosage stable least 5 day . 4 . If 96hour scan 21 day registration , scan need repeat . 5 . Patients must fail prior radiation therapy must interval great equal 4 week completion radiation therapy study entry . 6 . All patient must sign informed consent indicate aware investigational nature study . 7 . Patients must &gt; 18 year old , life expectancy &gt; 8 week . 8 . Patients must Karnofsky performance status &gt; 60 . 9 . Patients must recover toxic effect prior therapy : 4 week investigational agent , 4 week prior cytotoxic therapy , two week vincristine , 6 week nitrosoureas , 3 week procarbazine administration , 1 week noncytotoxic agent , e.g. , interferon , tamoxifen , thalidomide , cisretinoic acid , etc . ( radiosensitizer count ) . 10 . Patients must adequate bone marrow function ( ANC &gt; 1,200/mm3 , platelet count &gt; 100,000/mm3 , hemoglobin &gt; 10 gm/dl ) , adequate liver function ( SGOT bilirubin &lt; 2 time ULN ) , adequate renal function ( serum creatinine &lt; 1.5 mg/dL otherwise measure 24hour creatinine clearance &gt; 60 cc/min ) start therapy . These test must perform within 14 day prior registration . 11 . Patients must significant medical illness investigator 's opinion adequately control appropriate therapy would compromise patient ' ability tolerate therapy . 12 . This study design include woman minority , design measure difference intervention effect . 13 . Patients must active infection require IV antibiotic . 14 . Patients must pregnant nursing , patient ( men woman ) must willing practice birth control 2 month treatment Talampanel . Women childbearing potential ( WCBP ) must negative serum urine pregnancy test . In addition , sexually active WCBP must agree use adequate contraceptive method ( oral , injectable , implantable hormonal contraceptive ; tubal ligation ; intrauterine device ; barrier contraceptive spermicide ; vasectomized partner ) . Exclusion Criteria 1 . Patients , view treat physician , significant active cardiac , hepatic , renal , psychiatric disease ineligible would significantly increase risk use talampanel . 2 . No concurrent use standard chemotherapeutics investigative agent . 3 . Patients know active , lifethreatening malignancy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
</DOC>